Efficacy and Adverse Events During Janus Kinase Inhibitor Treatment of SAVI Syndrome

OBJECTIVES: Mutations affecting the TMEM173 gene cause STING-associated vasculopathy with onset in infancy (SAVI). No standard immunosuppressive treatment approach is able to control disease progression in patients with SAVI. We studied the efficacy and safety of targeting type I IFN signaling with...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:J Clin Immunol
Main Authors: Volpi, Stefano, Insalaco, Antonella, Caorsi, Roberta, Santori, Elettra, Messia, Virginia, Sacco, Oliviero, Terheggen-Lagro, Suzanne, Cardinale, Fabio, Scarselli, Alessia, Pastorino, Claudia, Moneta, Gianmarco, Cangemi, Giuliana, Passarelli, Chiara, Ricci, Margherita, Girosi, Donata, Derchi, Maria, Bocca, Paola, Diociaiuti, Andrea, El Hachem, May, Cancrini, Caterina, Tomà, Paolo, Granata, Claudio, Ravelli, Angelo, Candotti, Fabio, Picco, Paolo, DeBenedetti, Fabrizio, Gattorno, Marco
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2019
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7086512/
https://ncbi.nlm.nih.gov/pubmed/31144250
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10875-019-00645-0
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados